A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Barbara Davis Center

Principal Investigator
Photograph of Christopher Striebich,  MD, PhD

Christopher Striebich, MD, PhD

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers